Pfizer's 2019q1 global revenue is 13.1 billion US dollars, up 5%

May 7 / AP / -- on April 30, Pfizer announced its financial results in the first quarter of 2019: operating revenue in the first quarter of 2019 was $13.1 billion, an increase of 5% At the beginning of fy2019, Pfizer identified three major businesses in its commercial operations: Pfizer biopharmaceutical group is a science based innovative pharmaceutical business group, which includes all the original innovative pharmaceutical business (excluding health drugs) and a new hospital business department The latter is engaged in the global commercialization of Pfizer sterile injection and anti infective drugs, including Pfizer's contract production operation, Pfizer centreone Pfizer also classifies its bio similar drug portfolio into tumor, inflammation and immunity business, and some mature drug products into internal medicine business department Pfizer puqiang is a global business group focusing on brand drugs and generic drugs with expired patents, including 20 brands of solid oral preparations with expired patents, including lerica, Lipitor, loxorubicin, Viagra and Celebrex, as well as some generic drugs Health drugs include Pfizer's over-the-counter drugs (OTC) Highlights of Pfizer biopharmaceutical group's operating revenue in the first quarter of 2019, Pfizer biopharmaceutical group's operating revenue totaled 9.2 billion US dollars, up 7% The main driving factors are: the global revenue of eliquis increased by 36%, the main driving factors are the continuous use of non valvular atrial fibrillation, and the increase of market share of oral anticoagulants; The main driving factors of the 25% increase in global revenue of the company are as follows: – business growth in the international market is 107%, and sales in developed European markets, Japan and some emerging markets remain strong after listing; – business growth in the U.S market is 2%, and sales of approved metastatic breast cancer indications slow down; Global revenue growth of prevnar13 vaccine (prevnar13) increased by 10%, mainly driven by: – 31% growth in emerging markets, reflecting the overall positive impact associated with increased government procurement of vaccines for paediatric indications, as well as increased shipments associated with GAVI, partially offset by non repeat volumes associated with national immunization programmes for adults in the first quarter of 2018; – the U.S market grew by 6%, reflecting the government's increased procurement of vaccines for paediatric indications in the first quarter of 2019, partially offset by the continued decline in adult indication operating revenue caused by the decrease of the uninoculated population compared with the same period last year; the global revenue of xeljanz increased by 34%, mainly driven by: – the business growth in the international market was 89%, mainly reflecting the continuous use of rheumatoid arthritis indications and ulcerative colitis indications recently released in some developed markets; – the business growth in the U.S market was 18%, reflecting the strong growth of rheumatoid arthritis indications and the listing of psoriasis arthritis and ulcerative colitis indications Highlights of Pfizer's operating revenue in the first quarter of 2019, Pfizer's operating revenue totaled US $3.1 billion, an increase of 1%, which is reflected in: business growth in emerging markets by 25%, driven by strong sales driven business growth in China, mainly involving Lipitor, livejoy and Celebrex; Business growth in Japan was 10%, driven mainly by strong growth in lerica and Celebrex Pfizer CEO Dr eberler said: Our strong financial performance in the first quarter of 2019 was driven by the continued growth of some of our biopharmaceutical brands, mainly including eliquis, ibrance, prevnar13 and xeljanz, as well as the strong business growth of some of Pfizer's brands mainly in the Chinese market Our new business architecture is designed to maximize the growth of our current operating revenue and transform the company into a post-2020 growth period - we expect to maintain a medium single digit revenue growth by 2025 We have always attached great importance to the implementation of business strategy, the management of relevant expenses, the promotion of our R & D product line, and the prudent allocation of our assets, so as to ensure the continued success of Pfizer Our R & D product line is continuing to provide differentiated treatment methods, which are expected to improve the existing treatment standards in multiple treatment areas In the first four months of 2019, we obtained five regulatory approvals and proposed phase III data of xtandi, a drug for the treatment of metastatic hormone sensitive prostate cancer, and phase II immunogenicity data of our adult 20 valent pneumococcal vaccine candidate In the next few months of 2019, we look forward to the approval of these drugs in the United States: tafamidis, a first-line treatment for thyroxine related cardiomyopathy, bavencio inlyta, a combination of renal cell carcinoma (RCC), and our biological analogues, rituximab, bevacizumab and adamummab We also hope to get phase III clinical data of pf-04965842, a Janus kinase-1 (Jak1) inhibitor, for the treatment of moderate to severe atopic dermatitis in 2019 In addition, rivipansel for the vascular occlusion crisis of sickle cell disease is also under development Our current R & D product line offers us unprecedented opportunities to change the lives of millions of patients and create value for all our shareholders.